New hope for advanced pancreatic cancer: drug combo shows promise in early trial
NCT ID NCT06646055
First seen Mar 10, 2026 · Last updated May 23, 2026 · Updated 9 times
Summary
This study tests two experimental drugs (AK112 and cadonilimab) plus standard chemotherapy in people with stage IV pancreatic cancer that has spread. The goal is to see if the combination is safe and can shrink tumors or slow the cancer. About 110 adults who have not had prior treatment for metastatic disease will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology.
Wuhan, Hubei, China
Conditions
Explore the condition pages connected to this study.